Literature DB >> 7332899

Constitutive heterochromatin (C-banding) studies in patients with testicular malignancies.

M K Robson, J M Anderson, O M Garson, J P Matthews, T F Sandeman.   

Abstract

The heterochromatic index [qh/(p + q) X 100] is a quantitative measure of variations in the heterochromatic regions of C-banded cells which minimizes differential contraction of heterochromatic and euchromatic areas. Heterochromatic indices of the homologues of chromosomes #1, #9, #16, and Y were studied in the genotypes of 48 patients with germinal tumors and in 30 controls. The heterochromatic indices of chromosome #9 in patients showed statistically significant heteromorphism compared with controls. In addition, the heteromorphism was found to increase from the lower malignancy seminoma to the highly malignant teratoma. A similar but statistically nonsignificant pattern was seen in chromosome #16. No statistical difference in the mean of the heterochromatic indices was found in chromosomes #1 and Y. The difference in the mean heterochromatic index in chromosome #9 appeared to be due to an increase in the mean heterochromatic index in chromosome #9 appeared to be due to an increase in the amount of constitutive heterochromatin and not to a decrease.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7332899     DOI: 10.1016/0165-4608(81)90028-5

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  3 in total

1.  C heterochromatin variation in couples with recurrent early abortions.

Authors:  A Maes; C Staessen; L Hens; E Vamos; M Kirsch-Volders; M C Lauwers; E Defrise-Gussenhoven; C Susanne
Journal:  J Med Genet       Date:  1983-10       Impact factor: 6.318

2.  Constitutive heterochromatin studies in patients with solid tumors.

Authors:  S Suciu
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

3.  Laterality, maldescent, trauma and other clinical factors in the epidemiology of testis cancer in Victoria, Australia.

Authors:  J M Stone; D G Cruickshank; T F Sandeman; J P Matthews
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.